|
Volumn 204, Issue 5, 2014, Pages 331-332
|
The 25th anniversary of the launch of prozac gives pause for thought: Where did we go wrong
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
ANTIHISTAMINIC AGENT;
ANXIOLYTIC AGENT;
BENZODIAZEPINE DERIVATIVE;
DIPHENHYDRAMINE;
FLUOXETINE;
MEPROBAMATE;
MONOAMINE OXIDASE INHIBITOR;
NEUROTRANSMITTER;
PENICILLIN DERIVATIVE;
PSYCHOTROPIC AGENT;
SEROTONIN;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
TRANYLCYPROMINE;
TRICYCLIC ANTIDEPRESSANT AGENT;
ANXIETY;
CONSULTATION;
DRUG DEVELOPMENT;
DRUG EFFICACY;
DRUG MARKETING;
DRUG POTENCY;
DSM-III;
DYSTHYMIA;
ELECTROCONVULSIVE THERAPY;
GINKGO BILOBA;
HUMAN;
KINESIOTHERAPY;
LOW CARBOHYDRATE DIET;
MAJOR DEPRESSION;
MEDICAL PRACTICE;
MELANCHOLIA;
MENTAL DISEASE;
MIXED ANXIETY AND DEPRESSION;
MOOD;
OBSESSIVE COMPULSIVE DISORDER;
PATHOPHYSIOLOGY;
PHARMACODYNAMICS;
PROTEIN DIET;
PSYCHIATRIST;
REACTIVE DEPRESSION;
REVIEW;
SEROTONIN BRAIN LEVEL;
WEIGHT REDUCTION;
DEPRESSIVE DISORDER, MAJOR;
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS;
ANTIDEPRESSIVE AGENTS;
DEPRESSIVE DISORDER, MAJOR;
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS;
FLUOXETINE;
HUMANS;
|
EID: 84899728266
PISSN: 00071250
EISSN: 14721465
Source Type: Journal
DOI: 10.1192/bjp.bp.113.129916 Document Type: Review |
Times cited : (13)
|
References (12)
|